Develops engineered T cell therapies, led by rese-cel, for patients with autoimmune diseases treated in rheumatology, neurology and dermatology.
10-K for FY2025, filed Mar 23, 2026We are a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that…View ↗
Resecabtagene autoleucel, or rese-cel (formerly referred to as CABA-201), is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR…View ↗
In December 2025, we initiated a registrational trial with rese-cel for patients with dermatomyositis or anti-synthetase syndrome. In…View ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
−$53.1MView ↗
8-K, filed Nov 9, 2026
Cabaletta is presenting new rese-cel (resecabtagene autoleucel, formerly known as CABA-201) Phase 1/2 clinical data featuring…View ↗
From two strategies to CARTA focus
The older report described two approaches: CARTA, which depletes all B cells, and CAART, which targets disease-causing B cells. The latest report centers its development program on rese-cel and the CARTA approach.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 23, 2026We are a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that…View ↗
Resecabtagene autoleucel, or rese-cel (formerly referred to as CABA-201), is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR…View ↗
In December 2025, we initiated a registrational trial with rese-cel for patients with dermatomyositis or anti-synthetase syndrome. In…View ↗
Competes with Novartis Pharmaceuticals, Gilead Sciences, Bristol Myers Squibb, Johnson and Johnson, Legend Biotech, and Autolus
10-K for FY2025, filed Mar 23, 2026There are multiple companies with marketed CAR T therapies for the treatment of hematologic cancers, including Novartis Pharmaceuticals…View ↗
Loading...